1. Introduction {#s0005}
===============

Patterns and trends in drug utilization fuel high-level decisions in both public and private settings ([@b0105], [@b0050]). Governments may use data to alter funding programs, while other entities may use data to produce generic medicines or fund research programs relating to highly used drug classes ([@b0105], [@b0090]). Characterizing this information is essential for monitoring health and economic outcomes of such decisions over time. These data can also be used to assess the potential impact of world events, publication of influential clinical trials, media reports, or other considerations that affect medication usage in society ([@b0070]). International comparisons of utilization data provide benchmarking opportunities for countries to assess regional and global trends, as well as signaling suboptimal or overuse of target medications.

Drug utilization is determined by a number of factors, including disease prevalence, prescriber habits, patient demand and access to medications ([@b0025]). Other patient-level characteristics such as education, socioeconomic status, cultural beliefs, and even geographical region may also influence patterns of use ([@b0025], [@b0100], [@b0035]). Cross-national trending allows for identification of signals that may warrant further study of these conditions. Recently, there has been an increase in published literature describing cross-national trends in drug utilization for a variety of drug classes ([@b0055], [@b0110], [@b0075]). Despite well-established roles for rational opioid prescribing in the management of pain states, utilization of narcotic medications has often been subject to scrutiny due to real risks of addiction, dependence, and diversion for illicit use ([@b0115]). However, little is known from a cross-national perspective, including countries in the Middle East.

The Middle East is representative of a region that greatly varies in both population and wealth, with many countries, especially those belonging to the Gulf Cooperation Council (GCC), enjoying recent affluence due to natural resource interests. Qatar is one such country having recently launched plans to address several deficit areas in the health system, notably medication and patient safety issues. Specifically, the current Qatar National Health Strategy has outlined the need to educate health professionals regarding appropriate use of narcotics as inadequate pain management approaches has resulted in opioid administration almost exclusive to inpatient-based care settings ([@b0085]). It is unknown whether this pattern occurs throughout the Middle Eastern region, or is limited to Qatar and other GCC countries. Prior work has described palliative care initiatives in Qatar; however, there is a scarcity of published experience among other countries and across additional suitable medical indications to fully determine the overall/general status of opioid prescribing in the region ([@b0020], [@b0030], [@b0010], [@b0005]).

In order to provide a baseline assessment of narcotic utilization in Arabic-speaking countries, our objective was to characterize narcotic use in twelve Arabic-speaking nations located in the GCC and surrounding Middle Eastern nations. We also sought to explore and compare Middle East narcotic use with other geographical regions.

2. Methods {#s0010}
==========

Annual narcotic utilization estimates were used for analysis. These estimates are generated according to each country's actual utilization data obtained from the prior three years and are self-reported. For example, the 2013 estimates incorporated actual utilization data obtained from 2009 through 2011. Data were obtained from the International Narcotics Control Board (INCB) Narcotic Drugs -- Technical Reports which are freely available online ([@b0060]). Each annual report compiles member countries' estimates of their national narcotic requirements for the subsequent year.

Annual estimates are given as average consumption of narcotic drugs in defined daily doses per million inhabitants per day. The opioids included in this estimate are listed in [Table 1](#t0005){ref-type="table"}. For ease of comparison, the INCB transforms overall drug weight estimates into defined daily doses and the doses used for this transformation are also given in [Table 1](#t0005){ref-type="table"}. It is important to note that this transformation occurs for statistical purposes only and does not necessarily reflect the usual prescribed dose for each agent. However, it allows for a means of comparison between agents that accounts for differences in drug potency. It is also the best measure to assess countries, such as those in the Middle East, where actual prescribing data are unavailable.

Five years of data (2008--2012) were extracted from reports for 12 Arabic-speaking countries located within the Middle East region: Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Syria, United Arab Emirates and Yemen. Data for Iraq were not available in 2008. Annual narcotic utilization estimates extracted from each country's INCB report were evaluated and an additional category, labeled *Arabic Countries* and comprised of all these nations, was calculated to facilitate further international comparisons. Data for the annual narcotic estimates available in the 2010, 2011, and 2012 INCB reports were obtained for other world regions (Africa, Asia, Central America, Europe, North America, Oceania, and South America).

Once data were extracted, we conducted a population-based cross-sectional analysis of estimated average consumption of narcotic drugs in defined daily doses per million inhabitants, as defined by INCB. The primary outcome of this study was to report the annual estimate of narcotic drugs for each country or region. A secondary outcome was the rate of growth of estimated annual narcotic drugs per country or region. This study was approved by the Institutional Review Board at Qatar University.

3. Results {#s0015}
==========

3.1. Comparison of Arabic speaking countries {#s0020}
--------------------------------------------

In 2012 (2013 estimate), the Gulf States of Bahrain and Kuwait had the highest estimates (364 and 352 defined daily doses per million inhabitants per day, respectively), while Yemen and Iraq had the lowest estimates (9 and 6 defined daily doses per million inhabitants per day, respectively) ([Fig. 1](#f0005){ref-type="fig"}). Resource-rich countries such as Saudi Arabia, Qatar, and UAE had average estimates (250, 198, and 215 defined daily doses per million inhabitants per day, respectively). All countries had positive rates of growth, except Jordan and Lebanon (−1.75, −16.25 defined daily doses per million inhabitants per day, respectively). The countries with the highest rates of growth were again, Kuwait and Bahrain (52.75 and 43.75 defined daily doses per million inhabitants per day, respectively).

3.2. Comparison of Arabic speaking countries to world regions {#s0025}
-------------------------------------------------------------

There were substantial differences observed between world regions in narcotic utilization from 2010 through 2012 (see [Fig. 2](#f0010){ref-type="fig"}). The regions of North America, Oceania, and Europe had the highest observed values (32,264, 9978 and 7937 defined daily doses per million inhabitants per day, respectively). South America and Asia had slightly higher values (253 and 231 defined daily doses per million inhabitants per day, respectively) than Africa and Central America (91 and 87 defined daily doses per million inhabitants per day, respectively) in 2012. When the 12 Arabic-speaking countries were pooled, the calculated estimate was lower than all regions except for Africa and Central America (128 defined daily doses per million inhabitants per day). Of note, the only regions with declining rates in narcotic requirement estimates were North America and Arabic-speaking countries (−191.5 defined daily doses per million inhabitants per day and −26.1 defined daily doses per million inhabitants per day, respectively). The highest growth rates were observed in Oceania and Europe (745.5 defined daily doses per million inhabitants per day and 680.5 defined daily doses per million inhabitants per day, respectively).

4. Discussion {#s0030}
=============

This study assessed estimated narcotic requirements in 12 Arabic-speaking countries in the Middle East and compared these requirements to other geographic regions in the world. Great variability was found among these Arabic-speaking countries, with Kuwait and Bahrain having the highest estimates. Similarly, these two countries had the highest rates of growth in estimates from 2008 through 2012. When compared to seven other global regions, Arabic-speaking countries in the Middle East had one of the lowest estimates of annual narcotic requirements, only higher than Africa and Central America. Arabic-speaking countries, along with North America, had the only negative growth rate in estimates from 2010 through 2012.

These findings imply patient access to opioid therapy in the Middle East is disparate from most other places in the world and should be of concern. Specific implications of documented low estimates, relative to other regions, are not clear, yet patient health outcomes may be aversely influenced. Inadequate pain control is known to lead to other chronic medical problems such as anxiety and depression and is associated with higher rates of addiction and dependence ([@b0040]). Productivity may decrease, due to increased recovery times from poor mobilization and rehabilitation ([@b0045]). These considerations would also heavily burden healthcare systems in terms of patient management and disposition of care. As such, studies assessing low estimated narcotic use with patient-level outcomes are needed to establish baseline understanding of the importance of these implications in practice.

This study raises important points regarding the rationale for low narcotic use in Arabic-speaking countries versus other world regions. Culture and religious explanations have been previously suggested and should be further explored ([@b0080]). These countries predominantly follow Islamic principles, laws, and customs. Narcotic prescribing and/or consumption may be greatly influenced by religion, especially in situations where multiple non-opioid analgesic choices exist. Even when deemed medically necessary, considerations of prescribers or their patients may limit appropriate narcotic use by choice of drug, dose, or duration of therapy. For example, a survey of senior medical students completing their study in Saudi Arabia found poor knowledge and antiquated attitudes regarding opioid analgesia prescribing; nearly half considered pain a minor problem for cancer patients (41%) and believed it to be untreatable (46%). Sixty-eight percent limited opioid prescribing to patients with poor prognosis ([@b0065]). It is also possible that cultural positions may influence governments and regulatory bodies when developing policies and procedures restricting use of narcotics in practice. Studies are needed to further explore these considerations and to determine facilitators and barriers for optimizing use.

Observed discrepancies in estimated narcotic requirements between Arabic-speaking countries are also of concern. Affluent countries, such as GCC member states (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates), are investing efforts to develop world-class health systems based on Western standards and could be credited to the higher utilization rates among these countries. Iraq and Yemen had the lowest estimates, which may be a reflection of political instability present during the years of study ([@b0095]). The low estimates for Egypt may potentially be explained in part by previous reports commenting on the limited accessibility and availability of narcotics for medical use ([@b0015]). Of course, country-specific laws and regulations regarding narcotic manufacturing, importation, and distribution will also greatly influence utilization patterns. Governmental-level concerns of addiction and abuse risk may foster system-wide disincentives for appropriate opioid prescribing (such as compelling physicians to submit to a health ministry the patient documentation for each narcotic prescription). Costs of importing opioid agents to developing countries may also be prohibitive.

The findings of this study are important for future research. As suggested above, studies are needed to determine whether associations exist between low narcotic utilization and poor patient outcomes. Additionally, rationale for the findings must be investigated to determine facilitators and barriers for use of narcotics in practice. In order to do this, strong collaborations are required between regulatory bodies, health institutions, and researchers. Future opportunities may be development of educational programs or health promotion strategies in order to optimize the use of these agents in these countries.

Limitations of this study should be addressed. First, data used for this study were estimates only and did not reflect actual narcotic consumption or prescribing data. However, these are the best estimates available for these countries. Secondly, it is difficult to draw conclusions regarding rationale for discrepancies observed. Instead, as discussed above, this study generated many hypotheses for future testing relating to narcotic utilization in Arabic speaking countries. Lastly, it is unknown what optimal narcotic estimates should be for these countries. Although it seems use may be suboptimal when compared to other regions, there is no evidence that this is actually true. Future studies should address this point by assessing patient-level outcomes in target populations.

5. Conclusions {#s0035}
==============

This is the first study to examine narcotic utilization in the Middle East. It provides a baseline assessment for capturing trends and changes occurring over time. The primary finding of this study, that narcotic use is low in Arabic speaking countries, should be assessed further to determine whether patients are being adequately treated for pain. Facilitators and barriers can be examined in other studies designed to determine why international differences exist based on the hypotheses presented in this paper. If use is determined to be suboptimal, health promotion and education programs can be developed for target groups resistant to narcotic use and/or consumption with an overall goal of optimizing patient outcomes relating to pain management.
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![Estimated narcotic requirements for the 12 Arabic speaking countries in the Middle East (defined daily doses per million inhabitants per day vs. year).](gr1){#f0005}

![Worldwide comparisons of estimated narcotic requirements by geographical region (defined daily doses per million inhabitants per day vs. year).](gr2){#f0010}

###### 

Narcotic drug and defined daily dose (mg) as per INCB ([@b0060]).

  Narcotic drug                        Defined daily dose (mg)
  ------------------------------------ -------------------------
  Acetyldihydrocodeine                 40
  Alphaprodine                         120
  Anileridine                          65
  Bezitramide                          15
  Codeine (cough suppressant)          100
  Codeine (analgesic)                  240
  Dextromoramide                       20
  Dextropropoxyphene hydrochloride     200
  Dextropropoxyphene napsylate         300
  Difenoxin                            3
  Dihydrocodeine (cough suppressant)   100
  Dihydrocodeine (analgesic)           150
  Diphenoxylate                        15
  Dipipanone                           75
  Ethylmorphine                        50
  Fentanyl                             0.6
  Heroin                               30
  Hydrocodone                          15
  Hydromorphone                        20
  Ketobemidone                         50
  Levorphanol                          6
  Methadone                            25
  Morphine                             100
  Nicomorphine                         30
  Normethadone                         10
  Norpipanone                          18
  Opium                                100
  Oxycodone                            75
  Oxymorphone                          10
  Pethidine                            400
  Phenazocine                          20
  Phenoperidine                        4
  Pholcodine                           50
  Piminodine                           100
  Piritramide                          45
  Propiram                             100
  Thebacon                             15
  Tilidine                             200
  Trimeperidine                        200
